OPKO Announces Presentation of Data on Long-Acting Oxyntomodulin at Diabetes Conference
23 April 2014 - 5:06AM
Business Wire
OPKO Health, Inc. (NYSE: OPK) today announced that it will
present data on its long acting oxyntomodulin (MOD-6030) product on
April 25, 2014 at the 7th Diabetes Drug Discovery and Development
Conference being held in Cambridge, MA. Company scientists will
make an oral presentation discussing MOD-6030, the company's
long-acting GLP-1 and Glucagon dual agonist with potential for the
treatment of type 2 diabetes and obesity. Pre-clinical data shows
the drug induced a marked weight loss and food intake inhibition in
both animal models which were superior compared to those with
bi-daily injections of native OXM and to bi-daily injections of
existing marketed drugs.
The 7th Diabetes Drug Discovery and Development Conference is
being held April 23-25, in Cambridge, MA. For more information,
visit:
http://www.gtcbio.com/conference/diabetes-drug-discovery-and-development-overview.
ABOUT OPKO HEALTH, INC.
OPKO is a multinational biopharmaceutical and diagnostics
company that seeks to establish industry-leading positions in
large, rapidly growing markets by leveraging its discovery,
development and commercialization expertise and novel and
proprietary technologies. For more information, visit
http://www.opko.com.
This press release contains "forward-looking statements," as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), regarding product development efforts and
other non-historical facts about our expectations, beliefs or
intentions regarding our business, technologies and products,
financial condition, strategies or prospects, including statements
regarding our expectations about MOD-6030, whether MOD-6030 will
induce marked weight loss and food inhibition or have superior
performance compared to other drugs, and whether we will be able to
successfully develop, obtain approval for and launch sales of
MOD-6030. Many factors could cause our actual activities or results
to differ materially from the activities and results anticipated in
forward-looking statements. These factors include those described
in our filings with the Securities and Exchange Commission, as well
as risks inherent in funding, developing and obtaining regulatory
approvals of new, commercially-viable and competitive products and
treatments, including the risks that clinical trials for MOD-6030
may not be successful or achieve the expected results or
effectiveness, and may not generate data that would support the
approval or marketing of this product for the indications being
studied, that others may develop products which are superior to
MOD-6030, and that MOD-6030 may not have advantages or prove to be
superior over presently marketed products. In addition,
forward-looking statements may also be adversely affected by
general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press
release speak only as of the date the statements were made and we
do not undertake any obligation to update forward-looking
statements. We intend that all forward-looking statements be
subject to the safe-harbor provisions of the PSLRA.
OPKO Health, Inc.Steven D. Rubin or Adam Logal, 305-575-4100
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2024 to May 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From May 2023 to May 2024